Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

被引:577
作者
Moise-Broder, PA
Forrest, A
Birmingham, MC
Schentag, JJ
机构
[1] CPL Assoc, LLC, Amherst, NY 14226 USA
[2] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14222 USA
关键词
D O I
10.2165/00003088-200443130-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Vancomycin is commonly used to treat staphylococcal infections, but there has not been a definitive analysis of the pharmacokinetics of this antibacterial in relation to minimum inhibitory concentration (MIC) that could be used to determine a target pharmacodynamic index for treatment optimisation. Objective: To clarify relationships between vancomycin dosage, serum concentration, MIC and antimicrobial activity by using data gathered from a therapeutic monitoring environment that observes failures in some cases. Methods: We investigated all patients with a Staphylococcus aureus lower respiratory tract infection at a 300-bed teaching hospital in the US during a 1-year period. Clinical and pharmacokinetic information was used to determine the following: (i) whether steady-state 24-hour area under the concentration-time curve (AUC(24)) divided by the MIC (AUC(24)/MIC) values for vancomycin could be precisely calculated with a software program; (ii) whether the percentage of time vancomycin serum concentrations were above the MIC (%Time>MIC) was an important determinant of vancomycin response; (iii) whether the time to bacterial eradication differed as the AUC(24)/MIC value increased; (iv) whether the time to bacterial eradication for vancomycin differed compared with other anti-bacterials at the same AUC(24)/MIC value; and (v) whether a relationship existed between time to bacterial eradication and time to significant clinical improvement of pneumonia symptoms. Results: The median age of the 108 patients studied was 74 (range 32-93) years. Measured vancomycin AUC(24)/MIC values were precisely predicted with the A.U.I.C. calculator in a subset of our patients (r(2) = 0.935). Clinical and bacteriological response to vancomycin therapy was superior in patients with higher ( greater than or equal to400) AUC(24)/MIC values (p = 0.0046), but no relationship was identified between vancomycin %Time>MIC and infection response. Bacterial eradication of S. aureus (both methicillin-susceptible and methicillin-resistant) occurred more rapidly (p = 0.0402) with vancomycin when a threshold AUC24/MIC value was reached. S. aureus killing rates were slower with vancomycin than with other anti staphylococcal antibacterials (p = 0.002). There was a significant relationship (p < 0.0001) between time to bacterial eradication and the time to substantial improvement in pneumonia score. Conclusions: Vancomycin AUC(24)/MIC values predict time-related clinical and bacteriological outcomes for patients with lower respiratory tract infections caused by methicillin-resistant S. aureus.
引用
收藏
页码:925 / 942
页数:18
相关论文
共 72 条
[41]   Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus [J].
Moise, PA ;
Forrest, A ;
Bhavnani, SM ;
Birmingham, MC ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (20) :S4-S9
[42]   The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin [J].
Moise, PA ;
Forrest, A ;
Birmingham, MC ;
Schentag, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1017-1026
[43]  
Moise PA, 2000, INT J ANTIMICROB AG, V16, pS31, DOI 10.1016/S0924-8579(00)00303-4
[44]   Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo [J].
Mouton, JW ;
van Ogtrop, LL ;
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2473-2478
[45]   Standardization of pahrmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs [J].
Mouton, JW ;
Dudley, MN ;
Cars, O ;
Derendorf, H ;
Drusano, GL .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :355-358
[46]   Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin [J].
Nichols, RL ;
Graham, DR ;
Barriere, SL ;
Rodgers, A ;
Wilson, SE ;
Zervos, M ;
Dunn, DL ;
Kreter, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :263-273
[47]   ANTIBIOTIC TISSUE PENETRATION AND ITS RELEVANCE - IMPACT OF TISSUE PENETRATION ON INFECTION RESPONSE [J].
NIX, DE ;
GOODWIN, SD ;
PELOQUIN, CA ;
ROTELLA, DL ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (10) :1953-1959
[48]   ANTIBIOTIC TISSUE PENETRATION AND ITS RELEVANCE - MODELS OF TISSUE PENETRATION AND THEIR MEANING [J].
NIX, DE ;
GOODWIN, SD ;
PELOQUIN, CA ;
ROTELLA, DL ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (10) :1947-1952
[49]  
PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582
[50]   First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].
Ploy, MC ;
Grélaud, C ;
Martin, C ;
de Lumley, L ;
Denis, F .
LANCET, 1998, 351 (9110) :1212-1212